title: The in vitro construction of a tissue engineered bioprosthetic heart valve.
abstract: OBJECTIVE
  Heart valve replacement with either a nonliving xenograft or a mechanical prosthesis is an effective therapy for valvular heart disease. Both of these approaches have limitations, including their inability to grow, repair, and remodel. In addition, a mechanical prosthesis requires long-term anticoagulation therapy.
  
  
  METHODS
  This study demonstrates the in vitro creation of tissue engineered heart valve tissue using cardiovascular cells on degradable polymer matrices, 40 heart valve leaflets were created using this technique from two sources. Xenograft leaflets were created using human dermal fibroblasts and bovine aortic endothelial cells (n = 20) or allograft valve leaflets were created using sheep myofibroblasts and sheep endothelial cells (n = 20). A mixed sheep cell population was obtained consisting of endothelial cells and myofibroblasts. Endothelial cells were labelled with acethylated low density lipoprotein (Ac-Dil-LDL) and cells were separated into two groups using an activated cell sorter: LDL positive cells comprised of a pure endothelial cell population and LDL negative cells comprised of mixed cell population containing myofibroblasts and smooth muscle cells. The LDL negative cells were seeded on a synthetic polyglycolic acid (PGA) mesh and grown in vitro to form a tissue-like fibroblast-mesh core. Endothelial cells were then seeded onto the surface of the fibroblast-mesh core, forming a single monolayer.
  
  
  RESULTS
  Histological evaluation of these constructs revealed an inner core of LDL negative cells and outer endothelial-like cells which were factor VIII positive. There was no evidence of capillary formation from endothelial cells invading the myofibroblasts and smooth muscle matrix and the endothelial lining appeared complete.
  
  
  CONCLUSIONS
  It is feasible to construct allogenic heart valve tissue which could be used to make a valve.
authors.affiliation: Department of Cardiac Surgery, Children's Hospital, Harvard Medical School, Boston MA 02115, USA.
authors.forename: G
authors.initials: G
authors.lastname: Zund
authors.forename: C K
authors.initials: CK
authors.lastname: Breuer
authors.forename: T
authors.initials: T
authors.lastname: Shinoka
authors.forename: P X
authors.initials: PX
authors.lastname: Ma
authors.forename: R
authors.initials: R
authors.lastname: Langer
authors.forename: J E
authors.initials: JE
authors.lastname: Mayer
authors.forename: J P
authors.initials: JP
authors.lastname: Vacanti
mesh_terms: D000818:Animals; D001705:Bioprosthesis; D002417:Cattle; D002454:Cell Differentiation / Q000502:physiology; D004730:Endothelium, Vascular / Q000166:cytology; D005169:Factor VIII / Q000032:analysis; D005347:Fibroblasts / Q000166:cytology; D006350:Heart Valve Prosthesis; D006801:Humans; D007124:Immunoenzyme Techniques; D066298:In Vitro Techniques; D009131:Muscle, Smooth, Vascular / Q000166:cytology; D012756:Sheep
chemical_list: D005169:Factor VIII